Sixty-minute infusion rituximab protocol allows for safe and efficient workflow

详细信息    查看全文

• 作者：Emily Dotson ; Brooke Crawford ; Gary Phillips ; Jeffrey Jones
• 关键词：Rituximab ; Infusion reactions ; Hypersensitivity ; Lymphoma ; Sixty minutes
• 刊名：Supportive Care in Cancer
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：24
• 期：3
• 页码：1125-1129
• 全文大小：284 KB
• 参考文献：1.Rituxan® (2013) [package insert]. Genentech, Inc, South San Francisco
  2.Rituxan® (2000) [package insert]. Hoffmann-La Roche Ltd, Mississauga
  3.Common terminology criteria for adverse events (CTCAE): General disorders and administration site conditions. Version 4.02. September 10, 2009
  4.Aurran-Schleinitz T, Gravis G, Vittot M et al (2005) One hour rituximab infusion is safe and improves patient care and outpatient unit management. Blood 106:4759
  5.Sehn LH, Donaldson J, Filewich A et al (2007) Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 109(10):4171–4173
  6.Chiang J, Chan A, Shih V et al (2010) A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center. Int J Hematol 91(5):826–30
  7.Middleton HJ, Mollee P, Bird R et al (2005) Accelerated delivery of rituximab is safe on an out-patient basis. Blood 106:4777
  8.Siano M, Lerch E, Negretti L (2008) A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clin Cancer Res 14(23):7935–79359
  9.Ghielmini M, Negretti L, Lerch E et al (2005) Infusion speed-escalation trial to give full-dose rituximab in One hour without steroids Pre-medication. Blood 106:2451
  10.Lang DSP, Keefe DMK, Schultz T et al (2013) Predictors of acute adverse events from rapid rituximab infusion. Support Care Cancer 21(8):2315–20CrossRef PubMed
  11.Tuthill M, Crook T, Corbet T et al (2009) Rapid infusion of rituximab over 60 min. Eur J Haematol 82(4):322–5CrossRef PubMed
  12.Atay S, Barista I, Gundogdu F et al (2012) Rapid-infusion rituximab in lymphoma treatment: 2-year experience in a single institution. J Oncol Pract 8(3):141–143PubMedCentral CrossRef PubMed
  13.Dakhil, Hermann R, Schreeder MT, et al (2014) Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. Leuk Lymphoma 55(10):2335–2340
  14.Kallen M, Terrell J, Lewis-Patterson P et al (2012) Improving wait times for chemotherapy in an outpatient clinic at a comprehensive cancer center. J Oncol Pract 8(1):e1–e7PubMedCentral CrossRef PubMed
  15.Griffith N, Allen C, Pultz A et al (2008) The impact of a long-acting erythropoiesis stimulating protein on patient throughput in a hospital-based ambulatory oncology clinic. Hosp Pharm 43:388–395CrossRef
  16.Swan J, Zaghloul H, Cox J et al (2014) Use of a pharmacy protocol to convert standard rituximab infusions to rapid infusion shorten outpatient infusion clinic visits. Pharmacotherapy 34(7):686–694CrossRef PubMed
  
• 作者单位：Emily Dotson (1)
  Brooke Crawford (2)
  Gary Phillips (3)
  Jeffrey Jones (4)
  
  1. The Ohio State Comprehensive Cancer Center-James Cancer Hospital, 460 W. 10th Ave., Columbus, OH, 43210, USA
  2. Richard L Roudebush VA Medical Center, Indianapolis, IN, USA
  3. The Ohio State University Center for Biostatistics, Columbus, OH, USA
  4. Department of Internal Medicine, Division of Hematology, The Ohio State Comprehensive Cancer Center-James Cancer Hospital, Columbus, OH, USA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Nursing
  Nursing Management and Research
  Pain Medicine
  Rehabilitation Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-7339

文摘

Purpose Rituximab is a chimeric monoclonal antibody approved to treat B cell non-Hodgkin’s lymphoma (NHL). Infusion reactions among NHL patients are common during the first exposure but decrease with subsequent infusions. We sought to assess the safety and feasibility of a rituximab rapid infusion protocol in the outpatient treatment area of a comprehensive cancer center.